Rediscovery of Ceruletide, a CCK Agonist, as an Analgesic Drug

References

• Keppel Hesselink JM, Schatman ME. Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. J Pain Res. 2018;11:2991–2995. doi:10.2147/JPR.S186082
   Web of Science ®Google Scholar
• Keppel Hesselink JM. The quest for better analgesics for the treatment of peripheral neuropathic pain: navigating the sodium channels. Trends Gen Pract. 2018;2:2–3.
   Google Scholar
• Keppel Hesselink JM, Notermans NC. Topical phenytoin formulations for pain in small fiber neuropathy, a pathogenetic approach. Gen Int Med Clin Innov. 2018;3:2–4. doi:10.15761/GIMCI
   Google Scholar
• Kopsky DJ, Keppel Hesselink JM. Single-blind placebo-controlled response test with phenytoin 10% cream in neuropathic pain patients. Pharmaceuticals. 2018;11:122. doi:10.3390/ph11040122
   Web of Science ®Google Scholar
• Keppel Hesselink JM, Mulder JK, Kopsky DJ. Rationale for the repositioning of phenytoin as a topical analgesic for peripheral neuropathic pain and a personalized and investigator-driven development plan. Ann Pharmacol Pharm. 2018;3:1144.
   Google Scholar
• Keppel Hesselink JM. Kambo: A ritualistic healing substance from an amazonian frog and a source of new treatments. Open J Pain Med. 2018;2:004–006. doi:10.17352/ojpm.000007
   Google Scholar
• Keppel Hesselink JM. Kambô: a shamanistic ritual arriving in the West - description, risks and perception by the users. Int J Psychol Psychoanal. 2018;4:034.
   Google Scholar
• Basso N, Materia A, Fiocca F, et al. Treatment of biliary colic with ceruletide. Gastroenterology. 1980;78:1137.
   Web of Science ®Google Scholar
• Basso N, Materia A, Fiocca F, et al. Behandlung der gallenkolik mit ceruletid. Therapiewoche. 1981;31:2784–2786.
   Google Scholar
• Basso N, Bagarani M, Gizzonio D, et al. Analgesic effect of ceruletide (CRL) in biliary and renal colic. Gastroenterology. 1981;80:1165.
   Web of Science ®Google Scholar
• Basso N, Materia A, D’Intinosante V, et al. Effect of ceruletide on pituitary-hypothalamic peptides and on emotion in man. Peptides. 1981;2(Suppl 2):71–75. doi:10.1016/0196-9781(81)90014-0
   Web of Science ®Google Scholar
• Erspamer V, Roseghini M, Endean R, et al. Biogenic amines and active polypeptides in the skin of Australian amphibians. Nature. 1966;212:204. doi:10.1038/212204a0
   PubMed Web of Science ®Google Scholar
• Anastasi A, Erspamer V, Endean R. Isolation and structure of caerulein, an active decapeptide from the skin of Hyla caerulea. Experientia. 1967;23:699–700. doi:10.1007/BF02154119
   PubMedGoogle Scholar
• Erspamer V, Bertaccini G, De Caro G, et al. Pharmacological actions of caerulein. Experientia. 1967;23:702–703. doi:10.1007/BF02154121
   PubMedGoogle Scholar
• De Castiglione R, Di Salle E. Is commercial “cerulein” always true cerulein? Gastroenterology. 1980;78:1113–1114. doi:10.1016/0016-5085(80)90820-3
   Web of Science ®Google Scholar
• Approved Drug Products with Therapeutics Equivalence Evaluations (Orange Book). 38th ed. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf. Accessed December 27, 2019.
   Google Scholar
• CERULETIDE USES. Available from: https://www.ndrugs.com/?s=ceruletide. Accessed December 27, 2019.
   Google Scholar
• Takus 5 µg. Available from: https://medikamio.com/de-de/medikamente/takus-5-ug/pil. Accessed December 27, 2019.
   Google Scholar
• Yau W, Maklouf G, Edwards L, Farrar JT. Mode of action of cholecystokinin and related peptides on gallbladder muscle. Gastroenterology. 1973;65:451–456. doi:10.1016/S0016-5085(19)33077-X
   PubMed Web of Science ®Google Scholar
• Zetler G. Analgesia and ptosis caused by caerulein and cholecystokinin octapeptide (CCK-8). Neuropharmacology. 1980;19:415–422. doi:10.1016/0028-3908(80)90047-7
   Web of Science ®Google Scholar
• Baber NS, Dourish CT, Hill DR. The role of CCK, caerulein, and CCK antagonists in nociception. Pain. 1989;39:307–328. doi:10.1016/0304-3959(89)90045-6
   PubMed Web of Science ®Google Scholar
• Stacher G, Steinringer H, Schmierer G, et al. Ceruletide increases threshold and tolerance to experimentally induced pain in healthy man. Peptides. 1982;3:955–962. doi:10.1016/0196-9781(82)90064-X
   PubMed Web of Science ®Google Scholar
• Basso N, Pona V, Dintinosante V, et al. Effect of ceruletide on rest pain in patients with arterial insufficiency of the lower extremity. Eur J Clin Pharmacol. 1982;22:531–533. doi:10.1007/BF00609626
   Web of Science ®Google Scholar
• Dolecek R, Jezek M, Adámková M, et al. Endorphin releasers: a new possible approach to the treatment of pain after burns–a preliminary report. Burns Incl Therm Inj. 1983;10:41–44. doi:10.1016/0305-4179(83)90126-2
   Google Scholar
• Santamaria A, Lucani G, Montorsi M, et al. Action de la ceruleine sur la colique hepatique. Nouv Presse Med. 1979;8:2482.
   Google Scholar
• Saggioro A. Wirkung verschiedener dosen von ceruletide auf die schmerzen bei gallenkolik. Therapiewoche. 1981;31:2787.
   Google Scholar
• Piazza E, Brambilla M, Cattaneo MT, et al. Analgesic activity of ceruletide in cancer patients: abstracts of the International Symposium on Brain-Gut Axis, Florence, Italy 1981; abstract #146.
   Google Scholar
• Dolecek R, Kubis M, Sajnar J, et al. Endorphin releasers-a new method of pain management? Cas Lek Cesk. 1982;121:944.
   Google Scholar
• Malfertheiner P. Successful alleviation of migraine pain with short ceruletide infusion. Anaesthesist. 1983;32–1:33–35.
   Web of Science ®Google Scholar
• Pardo A, Celotti F, De Paolis C. Ceruletide analgesia in biliary colic. Clin Pharmacol Ther. 1984;36:510–514. doi:10.1038/clpt.1984.211
   Web of Science ®Google Scholar
• Stacher G, Steinringer H, Schmierer G, et al. Ceruletide increases dose dependently both jejunal motor activity and threshold and tolerance to experimentally induced pain in healthy man. Gut. 1984;25:513–519. doi:10.1136/gut.25.5.513
   Web of Science ®Google Scholar
• Basso N, Bagarani M, Materia A, et al. Effect of caerulein in patients with biliary colic pain. Gastroenterology. 1985;89:605–609. doi:10.1016/0016-5085(85)90457-3
   Web of Science ®Google Scholar
• Meyer-Lindau F, Pfister E, Gyr N, et al. Randomized double-blind study of the analgesic effect of caerulein and morphine in chronic tumor pain. Onkologie. 1988;11:77–80. doi:10.1159/000216492
   Google Scholar
• Pause BM, Drews C, Scherhag C, et al. Analgesic effect of ceruletide in men is limited to specific pain qualities. Physiol Behav. 1996;59:1025–1031. doi:10.1016/0031-9384(95)02230-9
   Web of Science ®Google Scholar
• Gullo L. Maximal effective dose of cerulein in the secretin-cerulein test. Digestion. 1988;39:225–229. doi:10.1159/000199630
   Web of Science ®Google Scholar
• Zetler G. Ceruletide, ceruletide analogues and cholecystokinin octapeptide (CCK-8): effects on motor behaviour, hexobarbital-induced sleep and harman-induced convulsions. Peptides. 1982;3:701–704. doi:10.1016/0196-9781(82)90174-7
   Web of Science ®Google Scholar
• Zetler G. Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam. Neuropharmacology. 1983;22:757–766. doi:10.1016/0028-3908(83)90100-4
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Nakahara T, Ushimura H, et al. Effect of systematically administered caerulein on dopamine metabolism in rat brain. Brain Res. 1984;325:195–199. doi:10.1016/0006-8993(84)90643-7
   Web of Science ®Google Scholar
• Roca-Lapirot O, Fossat P, Ma S, et al. Acquisition of analgesic properties by the cholecystokinin (CCK)/CCK2 receptor system within the amygdala in a persistent inflammatory pain condition. Pain. 2018.
   Web of Science ®Google Scholar